Alnylam Presents Positive Complete Results from ENVISION Phase 3 Study of Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyria

Press/Media

Period12 Apr 2019

Media coverage

1

Media coverage

  • TitleAlnylam Presents Positive Complete Results from ENVISION Phase 3 Study of Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyria
    Media name/outletIndia Pharma News
    Country/TerritoryIndia
    Date12/04/19
    PersonsManisha Balwani
View all 1
View less